Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2021-04-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2020年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2020年度募集资金存放与使用情况专项报告" which translates to "2020 Annual Special Report on the Deposit and Use of Raised Funds." It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds by listed companies. The content details the amount of funds raised, their usage, management, and compliance with regulatory requirements. It includes detailed tables on fund usage, investment projects, and audit opinions from an accounting firm. The document is a comprehensive report on the management and use of capital raised by the company, not merely an announcement or a brief summary. It is not a general annual report or earnings release but a specialized report focused on capital raised and its deployment. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (15,000 characters) and detailed financial data support this classification with high confidence.
2021-04-23 Chinese
2020年度独立董事述职报告（陈思东）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2020 by an independent director of the company. It details the director's attendance at board and shareholder meetings, opinions on various company matters, committee work, on-site inspections, investor protection efforts, training, and other work during the year. It is a narrative report on the director's duties and activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. This type of document fits best under Board/Management Information (MANG) as it relates to the activities and reports of a board member, specifically an independent director's report on their duties and opinions.
2021-04-23 Chinese
海通证券关于康芝药业募集资金2020年度存放与实际使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the 2020 annual special audit opinion on the deposit and actual use of raised funds by Kangzhi Pharmaceutical Co., Ltd. It includes extensive financial data on fundraising amounts, usage, balances, management systems, agreements, and investment projects related to the raised funds. The document references regulatory guidelines and compliance with securities regulations. It is a comprehensive audit and verification report on the use of funds raised through an IPO and subsequent capital activities, including detailed tables and explanations of fund usage and project progress. The document is lengthy (over 14,000 characters) and contains substantive financial and operational data, not merely an announcement or certification. This fits the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific financial aspects, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-04-23 Chinese
2020年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2020 年度监事会工作报告' which translates to '2020 Supervisory Board Work Report'. It details the supervisory board's activities during the 2020 fiscal year, including meetings held, review of financial reports, internal controls, use of raised funds, asset transactions, related party transactions, guarantees, and internal control evaluations. The document contains substantive content about the company's governance and supervisory activities over the year, including financial oversight and compliance. It is not a full annual report (10-K) but a specific report from the supervisory board on their work and oversight for the year. This type of document aligns with the category of Audit Report / Information (AR), as it includes audit opinions, internal control evaluations, and supervisory board oversight reports, which are distinct from the full annual report. The document length (4843 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-04-23 Chinese
2020年年度审计报告
Audit Report / Information Classification · 100% confidence The document is an audit report for 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.) for the fiscal year ending December 31, 2020. It contains detailed auditor opinions, audit basis, key audit matters such as revenue recognition and goodwill impairment testing, responsibilities of management and auditors, and extensive notes on accounting policies and financial statement preparation. The document includes financial statement notes and detailed accounting policies, indicating it is the full audit report rather than a brief announcement or certification. The length of the document (15,000 characters) and the presence of comprehensive audit content confirm it is a standalone Audit Report. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2020
2021-04-23 Chinese
独立董事关于第五届董事会第十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various company matters related to the 2020 fiscal year, including profit distribution, fundraising usage, internal control self-evaluation, securities investment, related party transactions, credit facilities, and external guarantees. It references compliance with regulatory guidelines and internal company rules. The content is detailed and substantive, focusing on governance and oversight rather than just announcing or summarizing financial results. It does not contain full financial statements or quarterly results, nor is it a simple announcement or certification. The document fits best as a Board/Management Information filing, as it relates to board opinions and governance matters concerning company operations and compliance.
2021-04-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.